Tecentriq: Ph Ib data

Preliminary data from an open-label, U.S. Phase Ib trial in 29 evaluable patients with previously untreated BRAF V600 mutation-positive unresectable or advanced melanoma showed that 800 mg IV Tecentriq every 2 weeks plus Cotellic cobimetinib and Zelboraf vemurafenib led to an ORR of 83%, including 3 complete responses and 21 partial responses. Median duration of response and PFS were not reached. Data was presented at the European Society for Medical Oncology meeting in Copenhagen. A Phase III trial is evaluating Tecentriq plus Cotellic and Zelboraf to treat previously untreated BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma...